Ascendis Pharma A/S

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 10/09/2024 am IST			5-day change	1st Jan Change
116.84 ^USD	-1.94%		-15.61%	-7.23%

05/09	Oppenheimer Upgrades Ascendis Pharma A/S to Outperform From Perform, $180 Price Target	MT
04/09	European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Ascendis Pharma A/S

Oppenheimer Upgrades Ascendis Pharma A/S to Outperform From Perform, $180 Price Target	05/09	MT
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	04/09	MT
Sector Update: Health Care Stocks Fall Premarket Wednesday	04/09	MT
Royalty Pharma, Ascendis Pharma Unit Have $150 Million Royalty Funding Agreement	04/09	MT
Ascendis Pharma Q2 Loss Narrows, Sales Slump -- Shares Plunge After Hours	04/09	MT
Earnings Flash (ASND) ASCENDIS PHARMA Reports Q2 Revenue EUR36M	04/09	MT
Ascendis Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	04/09	CI
Transcript : Ascendis Pharma A/S, Q2 2024 Earnings Call, Sep 03, 2024	04/09
Evercore ISI Raises Price Target on Ascendis Pharma to $200 From $191, Keeps Outperform Rating	26/08	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	22/08	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	13/08	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	12/08	MT
Sector Update: Health Care Stocks Flat to Higher Pre-bell Monday	12/08	MT
Ascendis Pharma Shares Climb on U.S. FDA Approval for Hypoparathyroidism Treatment Yorvipath	12/08	DJ
Sector Update: Health Care	12/08	MT
Transcript : Ascendis Pharma A/S - Special Call	12/08
Ascendis Pharma Gets U.S. FDA Approval for Hypoparathyroidism Treatment	12/08	DJ
Ascendis Pharma Gets US FDA Approval of Hypoparathyroidism Therapy	12/08	MT
FDA approves Ascendis Pharma's hormone disorder therapy	12/08	RE
Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults	12/08	CI
European Equities Traded in the US as American Depositary Receipts Sharply Down in Friday Trading	02/08	MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Sharply Lower Thursday	01/08	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	30/07	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday	18/07	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	09/07	MT

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Employees

879

Sector

Biotechnology & Medical Research

Calendar

06/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company